For pharmaceutical manufacturers, sponsors, and life sciences organizations operating in the Australian market, ensuring the ongoing safety of therapeutic goods is not just a best practice—it is a mandatory obligation. The moment a medicine is approved and listed on the Australian Register of Therapeutic Goods (ARTG), the post-market safety surveillance begins, overseen by the demanding...